ATS Scientific Products

Research, industry and healthcare professionals throughout the world rely on ATS Scientific Products' synergistic collection of fill-finish drug manufacturing solutions, freeze dryers, durable benchtop equipment, laboratory apparatus and scientific glassware to keep their manufacturing and research running smoothly and efficiently. Our market leading brands of scientific products include Genevac, VirTis, Hull, PennTech, i-Dositecno, FTS, Hotpack, Bel-Art, H-B Instrument, Ableware, Wilmad-LabGlass and Service, and represent over 400 combined years of experience, quality and innovation. Headquartered in Warminster, PA, Scientific Products has manufacturing locations throughout the United States and Europe. Explore and learn more about why we are proud to be a trusted partner by leading organizations in Pharmaceuticals, Life Science, Higher Education, Ophthalmic, PetroChemical, Clinical Diagnostics, Food & Beverage Production, Environmental Testing and Monitoring and more. Scientific Products – Where your confidence is our success!

Symbiance

Symbiance was founded in 90's and established as a technology enabled Global CRO. We are experts in delivering innovative AI enabled products, data solutions, medical writing, drug safety, and Regulatory management for pharmaceutical/bio-tech companies. At Symbiance, we are a trusted partner to our clients, helping to bring medical breakthroughs to market quickly, accurately and cost effectively. With a combined 100 years of experience, dedication to personalized communication, and a relationship for success, Symbiance delivers numbers that matter. Symbiance is a renowned niche provider of Clinical data management, Clinical data standards, Biostatistics Statistical Programming Medical writing Pharmacovigilance Regulatory Operations Symbiance’s values Provide clients with faster solutions using advanced technologies with un-compromised quality. Establish and maintain open/transparent partnership with our clients. Symbiance is about, "creating relationships for success".

Kiniksa Pharmaceuticals

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company. Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.

Phathom Pharmaceuticals

Phathom Pharmaceuticals (Nasdaq: PHAT) is a biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, holding ourselves accountable to be equitable and just, and authentically supporting the people and communities impacted by our work, we strive to create a sense of inclusion and belonging. We are looking for self-motivated, creative problem solvers who are excited by the idea of working in a fast-paced start-up environment and contributing to our growth.

Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.